Immunotherapy and immunochemotherapy in combating visceral leishmaniasis
Visceral leishmaniasis (VL), a vector-borne disease, is caused by an obligate intramacrophage, kinetoplastid protozoan parasite of the genus Leishmania. Globally, VL is construed of diversity and complexity concerned with high fatality in tropics, subtropics, and Mediterranean regions with ~50,000–9...
Main Authors: | Ganesh Yadagiri, Aakriti Singh, Kanika Arora, Shyam Lal Mudavath |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-05-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1096458/full |
Similar Items
-
Immunotherapy and immunochemotherapy in visceral leishmaniasis: promising treatments for this neglected disease
by: Bruno Mendes Roatt, et al.
Published: (2014-06-01) -
Immunochemotherapy in American cutaneous leishmaniasis: immunological aspects before and after treatment
by: VPCP Toledo, et al.
Published: (2001-01-01) -
Can We Harness Immune Responses to Improve Drug Treatment in Leishmaniasis?
by: Raphael Taiwo Aruleba, et al.
Published: (2020-07-01) -
Immunotherapy and Targeted Therapies in Treatment of Visceral Leishmaniasis: current status and future prospects
by: Om Prakash eSingh, et al.
Published: (2014-06-01) -
Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy
by: Alti Dayakar, et al.
Published: (2019-04-01)